Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1978 3
1979 2
1981 1
1982 4
1983 1
1987 2
1988 3
1989 3
1990 5
1991 5
1992 7
1993 15
1994 9
1995 8
1996 5
1997 10
1998 8
1999 6
2000 6
2001 3
2002 3
2003 5
2004 9
2005 8
2006 12
2007 11
2008 3
2009 7
2010 9
2011 9
2012 9
2013 11
2014 15
2015 8
2016 14
2017 15
2018 21
2019 23
2020 32
2021 26
2022 21
2023 31
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Lee JW, et al. Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0. Lancet Haematol. 2023. PMID: 38030318 Clinical Trial.
Electrogenerated base-promoted cyclopropanation using alkyl 2-chloroacetates.
Matsumoto K, Hayashi Y, Hamasaki K, Matsuse M, Suzuki H, Nishiwaki K, Kawashita N. Matsumoto K, et al. Among authors: nishiwaki k. Beilstein J Org Chem. 2022 Aug 29;18:1116-1122. doi: 10.3762/bjoc.18.114. eCollection 2022. Beilstein J Org Chem. 2022. PMID: 36105721 Free PMC article.
Reply to the letter.
Tamura T, Mori A, Nishiwaki K. Tamura T, et al. Among authors: nishiwaki k. J Anesth. 2021 Feb;35(1):164. doi: 10.1007/s00540-020-02892-7. Epub 2021 Jan 8. J Anesth. 2021. PMID: 33416993 No abstract available.
371 results